Skip to main content
Clinical Trials/EUCTR2014-003811-13-NL
EUCTR2014-003811-13-NL
Active, not recruiting
Phase 1

Selecting cancer patients for treatment using Tumor Organoids, the SENSOR study - SENSOR

Antoni van Leeuwenhoek - Netherlands Cancer Institute0 sites70 target enrollmentMarch 23, 2016

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Colorectal cancer and non-small cell lung cancer
Sponsor
Antoni van Leeuwenhoek - Netherlands Cancer Institute
Enrollment
70
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 23, 2016
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
Antoni van Leeuwenhoek - Netherlands Cancer Institute

Eligibility Criteria

Inclusion Criteria

  • 1\.Patients with locally advanced (incurable) or metastatic colorectal cancer or NSCLC that have only one line standard of care treatment left, or will start with a study treatment. Patients should have received a first line standard of care treatment.
  • 2\.Patients for whom treatment with curative intent is not an option
  • 3\.RECIST 1\.1 evaluable metastatic or locally advanced lesion(s).
  • 4\.Metastatic or locally advanced lesion(s) of which a histological biopsy can safely be obtained
  • 5\.Adequate kidney and liver function.
  • 6\. WHO performance status 0\-1
  • 7\. Informed consent
  • 8\. 18 years or older
  • Additional in\- and exclusion criteria are provided for each experimental compound
  • Are the trial subjects under 18? no

Exclusion Criteria

  • 1\.Pregnant or lactating (nursing) women
  • 2\.Prior malignancy within 5 years. Patients with a history of non\-melanomatous skin cancer, successfully treated carcinoma in situ or with a disease free period of \> 5 years may be included.
  • 3\.Known infection with human immunodeficiency virus (HIV).
  • 4\.Leptomeningeal carcinomatosis.
  • 5\.Symptomatic brain metastasis. Patients that are asymptomatic and have been stable for 3 months (confirmed by MRI/CT scan) are eligible for participation if they are not receiving corticosteroid therapy or anti\-epileptic drugs.
  • 6\.Other psychiatric or medical conditions that would make the patient unfit for participation due to an increase in the risk associated with study participation or incompliance with study procedures.
  • 7\.Life expectancy of less than 3 months from tumor progression under standard of care.
  • Additional in\- and exclusion criteria are provided for each experimental compound

Outcomes

Primary Outcomes

Not specified

Similar Trials